8 clinical trials found.
-
A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma and Other Rare Skin Tumors
The purpose of the study is to determine the safety and efficacy of talimogene laherparepvec monotherapy followed by combination therapy with nivolumab (NIVO) for patients ... -
A Randomized Controlled Open-Label Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma
This trial is being done to see whether Cemiplimab in combination with RP1 can reduce the size of your tumor(s) better than Cemiplimab alone ... -
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810) ADMINISTERED INTRALESIONALLY FOR PATIENTS WITH RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)
The main purpose of this study is to determine the safet and tolerability of cemiplimab. Cemiplimab-rwic is only approved by the U.S. Food and ... -
SpotCheck: Comparison of Enhanced Telemedicine Versus In-Person Evalution for the Diagnosis of Skin Cancer.
The aim of this pilot is to test a novel, telemedicine-based skin lesion diagnostic platform (SpotCheck) that has the potential to improve access to needed ...
-
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma
The main purpose of this study is to test the safety, tolerability, and effectiveness of the study drug tocilizumab when given with the drugs ipilimumab ... -
A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of TRQ15-01 administered i.v. in patients with relapsed ... -
MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable
The purpose of this research study is to: • Test the safety of the study drug, pembrolizumab (MK-3475) • Test how your cancer responds to one of ... -
Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
The purpose of this phase I study is to evaluate the safety and tolerability of MK-3475 (Pembrolizumab), a PD-1/PD-L1 blocking agent in patients with ...
